OUTSOURCE
IMMUNOHISTOCHEMISTRY: dIGITAL bREAST CANCER PANEL 3 (Z714)
Also Known As:
IMMUNOHISTOCHEMISTRY: dIGITAL bREAST CANCER PANEL 3
About This Test
ER & PR receptor assays are routinely performed on Breast carcinomas to assess responsiveness to endocrine therapy and prognosis. Her-2 expression shows responsiveness to Herceptin therapy. Reporting through digital images using Visiopharm AI algorithms enhances the sensitivity of the assay.
Test Parameters (1)
- IMMUNOHISTOCHEMISTRY: DIGITAL BREAST CANCER PANEL 3
Home Collection
✓ Available
Reports Available In
1 Day
Frequently Asked Questions
Outsourced test are being done from Dr. Lal Path Lab. Charges and reporting time is same as of Dr. Lal Path Labs.
Provide a copy of the Histopathology report.
The Digital Breast Cancer Panel-3 is an IHC test performed on breast tissue samples to evaluate key biomarkers that help determine tumor type, aggressiveness, and treatment options. This panel provides essential information for diagnosis, prognosis, and personalized therapy.
TAT Policy
The Turnaround Time (TAT) depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
In uncommon circumstances, TAT may be delayed due to test complexity or reasons beyond our control. You will be informed of the estimated TAT at the time of registration.
